Objective: To explore the difference of peripheral blood mononuclear cells (PBMC) transcripts between atopic dermatitis (AD) and healthy controls, and to screen and preliminarily validate potential biomarkers of AD. Methods: From January 2021 to May 2022, blood samples from 9 AD patients and 10 healthy controls were collected from the Dermatology and Cosmetic Center of the Third Affiliated Hospital of Chongqing Medical University, ribonucleic acid-sequencing (RNA-seq) was used to determine the transcriptome and relative expression of PBMC, the differentially expressed genes (DEGs) were analyzed by gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction networks (PPI) analysis, and the potential biomarkers were identified by quantitative real-time PCR (qRT-PCR). Results: The age of patients in the AD group [M (Q1, Q3)] was 26.50 (22.75, 30.50) years old, and the course of disease [M (Q1, Q3)] was 15 (10, 20) years,and the age of the healthy control group [M (Q1, Q3)] was 37.00 (27.75, 40.25) years old. Compared with healthy controls, 1 044 DEGs were detected in PBMC samples in AD group, including 668 up-regulated genes and 376 down-regulated genes. Differential variable splicing (AS) showed that mutually exclusive exons (46.74%) and skipped exon (31.01%) accounted for a large proportion. GO and KEGG enrichment analysis revealed that AD is closely linked to DEGs implicated in the inflammatory response and cytokine interaction and signal pathway. Comprehensive enrichment analysis and PPI analysis selected the expression of 8 candidate genes (CCL4, CCR3, CXCR5, NFKBIA, CXCL1, IL-1B, CCL20, LY96), which was confirmed by qRT-PCR and were consistent with that of RNA-seq. Conclusions: CCL4, CCR3, CXCR5, NFKBIA, CXCL1, IL-1B, CCL20 and LY96 might be potential biomarkers of AD, participating in the occurrence and development of AD.
目的： 探索特应性皮炎（AD）与健康对照者外周血单个核细胞（PBMC）转录组差异，筛选出AD潜在的生物标志物并进行初步验证。 方法： 收集2021年1月至2022年5月在重庆医科大学附属第三医院皮肤整形美容中心9例AD患者及10名健康对照者的外周血，提取PBMC后以RNA转录组测序（RNA-seq）技术进行转录组测序及相对表达量测定，通过对差异表达基因（DEGs）进行基因本体论（GO）、京都基因与基因组百科全书（KEGG）及蛋白互作网络（PPI）分析筛选出生物标志物候选基因并进行实时荧光定量PCR（qRT-PCR）进行初步验证。 结果： 病例组患者的年龄［M（Q1，Q3）］为26.50（22.75，30.50）岁，病程［M（Q1，Q3）］为15（10，20）年。健康对照组的年龄［M（Q1，Q3）］为37.00（27.75，40.25）岁。相对于健康对照者，AD组共检测出DEGs 1 044条，其中上调基因668条，下调基因376条，DEGs经差异可变剪切（AS）分析显示外显子选择性跳跃（46.74%）及外显子跳跃（31.01%）占比较大，GO富集分析显示DEGs主要与炎症反应相关，KEGG富集分析显示DEGs主要与细胞因子相互作用及信号通路相关。综合富集分析及PPI分析筛选出趋化因子C-C基序趋化因子配体4（CCL4）、C-C 基序趋化因子受体3（CCR3）、C-X-C 基序趋化因子受体 5（CXCR5）、核因子κB抑制因子-α（NFKBIA）、C-X-C基序趋化因子配体1（CXCL1）、白细胞介素1B（IL-1B）、C-C基序趋化因子配体20（CCL20）、淋巴细胞抗原96（LY96）作为AD生物标志物的候选基因，qRT-PCR验证显示上述细胞因子及细胞因子受体mRNA相对表达量与转录组测序结果趋势一致。 结论： CCL4、CCR3、CXCR5、NFKBIA、CXCL1、IL-1B、CCL20、LY96可能为AD的潜在生物标志物，参与AD的发生及发展。.